However, the association between NRF2 expression and radioresistance of cancer cells in various tumor types, as in lung cancer (156, 157), prostate cancer (158), and nasopharyngeal cancer (159), renders it a good therapeutic target to increase the sensitivity to the treatment. Here, NFE2L2 is linked to lung carcinoma.